A randomized phase I/II pilot study of intermittent withdrawal of antiretroviral therapy as an immunization strategy and double-blinded immunization with ALVAC-HIV vCP1452 in subjects with persistent CD4+ cell counts greater than 400 cells/mm3 and plasma HIV-1 RNA levels less than 50 copies/mL

Trial Profile

A randomized phase I/II pilot study of intermittent withdrawal of antiretroviral therapy as an immunization strategy and double-blinded immunization with ALVAC-HIV vCP1452 in subjects with persistent CD4+ cell counts greater than 400 cells/mm3 and plasma HIV-1 RNA levels less than 50 copies/mL

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Jul 2013

At a glance

  • Drugs Antiretrovirals; HIV vaccine vCP1452
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 May 2012 Actual patient number changed from 97 to 94 as reported by ClinicalTrials.gov.
    • 05 Oct 2007 Status changed from in progress to completed.
    • 15 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top